An international team in RNA biology, aptamers and drug development
Aptadir's founders come from Beth Israel Deaconess Medical Center, the Italian National Research Council, the Cancer Science Institute of Singapore and City of Hope.
Board of directors

Giovanni Amabile, PhD
Founder, CEO and Executive Chairman
Previously CEO of Enthera, where he secured the largest VC-backed Series A for an Italian biotech, and CSO at ADIENNE, where he achieved US marketing approval for thiotepa in 2017.

Simone Braggio
Board member
Over 30 years in Big Pharma (GSK and affiliates) and CROs (Aptuit, Evotec), in research, strategic partnerships and new business models.

Davide Santi
Board member
Investment career from Amadeus Capital Partners to an Italian healthcare fund, with health economics and market access roles at Amgen and UCB.
Scientific founders

Annalisa Di Ruscio, MD, PhD
Over 15 years in RNA biology and DNA methylation, focused on blood cancers including MDS. Co-founder of SpeaRNA.

Vittorio De Franciscis, PhD
Over 35 years of expertise in aptamer technology.

Daniel G. Tenen, MD
Over 30 years in gene regulation of normal and cancer cells, a leader in leukemia research. Co-founder of Believer Inc. and SpeaRNA.

Marcin Kortylewski, PhD
Over 20 years in oligonucleotide therapeutics. Co-founder of Duet BioTherapeutics.
Investors
A €40 million seed round in September 2026, the largest biotech seed financing in Italy.
- 4BIO Capital
- Extend
- CDP Venture Capital
- XGEN Venture
- CE-Ventures
Partners and investors
For partnering, licensing or investment conversations, write to the team in Milan.
Contact the team